+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Devic's Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029

  • PDF Icon

    Report

  • 114 Pages
  • October 2021
  • Region: Global
  • Acute Market Reports
  • ID: 5614482

Industry Outlook


Devic’s syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 194.4 Mn in 2020 and projected to grow at a CAGR of 12.0% during the forecast period from 2021 to 2029. Devic's disease or neuromyelitis optica is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord, but in a few cases affect the brain. The injury to optical nerves leads to inflammation and soreness leading to vision loss and pain; the injury to the spinal cord leads to paralysis in the arms or legs, loss of sensation, and problems with bladder & bowel function. The key factors responsible for growth of global Devic’s syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.

Soliris (Eculizumab) will aid the significant growth of Devic’s Syndrome treatment market throughout the forecast period


Soliris (Eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic’s syndrome. Patients suffering with Devic’s syndrome possess AQP4 antibody-positive, the body’s immune system can turn against itself to produce autoantibodies against AQP4. Activation of anti-AQP4 autoantibodies leads to damage of vital cells in the CNS assisting further demyelination and death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in Devic’s syndrome treatment pipeline such as Satralizumab - Phase 3 (Hoffmann-La Roche/ Chugai Pharmaceutical), MEDI-551- Phase 2/3 (MedImmune LLC), and RC18 - Phase 3 (RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on 15 October 2020; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

North America dominated the overall global market specifically due to recent drug approval, promising drugs in pipeline, and developed diagnostic landscape


In 2020, North America dominated the market and anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirement for target-specific molecules to treat Devic’s Syndrome, and easy adaptability & accessibility for newly launched drug. According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic’s syndrome in the United States with majority of women population. Asia Pacific will grow during the forecast period from 2021 to 2029, due to increasing awareness related to Devic’s Syndrome assisting the rise in diagnosis & treatment rate in patients suffering with rare diseases.

Historical & Forecast Period


The Devic’s Syndrome treatment market analyzed considering current market trends for base year 2020 and based on future trends CAGRs calculated for the forecast period from 2021 to 2029.

Report Scope by Segments


This report comprises in-depth information related to the Devic’s Syndrome treatment market along with major factors affecting or assisting market such as opportunities, drivers, & restraints. A descriptive data covering market drivers, challenges & opportunities provided specifically for country-level and regional segmentation. This report covered detailed info related to the global Devic’s syndrome treatment market segmented based on drug type, and geography. The report also include pipeline analysis of upcoming drugs, competitive analysis of the major companies present in Devic’s Syndrome treatment market including detailed data related to the competitive landscape of the market and the recent market strategies & products pipeline.

The major companies involved in the Devic’s Syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd. among others.

Key questions answered in this report

  • Which is the most desired drug used to manage & treat Devic’s syndrome & Why?
  • What are the recent market strategies followed by the key companies & competitive landscape of the Devic’s syndrome treatment market?
  • Which are the current and future key geographical markets (regions and countries) in Devic’s syndrome treatment?
  • Which is the fastest and largest growing Devic’s syndrome treatment segment globally?
  • What are the drivers, restraints, & opportunities in the Devic’s syndrome treatment market?


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global DST Market Portraiture
2.2. Global DST Market, by Type of Drug, 2020 (US$ Mn)
2.3. Global DST Market, by Geography, 2020 Vs 2029 (Value %)
Chapter 3. Global Devic’s Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2020
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2020
Chapter 4. Global Devic’s Syndrome Treatment (DST) Market, by Type of Drugs, 2019 - 2029 (US$ Mn)
4.1. Overview
4.2. Eculizumab
4.3. Methylprednisolone
4.4. Azathioprine
4.5. Mycophenolate Mofetil
4.6. Rituximab
Chapter 5. Global Devic’s Syndrome Treatment (DST) Market, Pipeline Analysis
5.1. Overview
5.2. Satralizumab - Phase III (Hoffmann-La Roche/ Chugai Pharmaceutical)
5.3. MEDI-551 - Phase II/III (MedImmune LLC)
5.4. RC18 - Phase III (RemeGen, Ltd.)
Chapter 6. Global Devic’s Syndrome Treatment (DST) Market, by Geography, 2019 - 2029 (US$ Mn)
6.1. Overview
6.2. North America DST Market Analysis, 2019 - 2029
6.2.1. North America DST Market, by Type of Drugs, 2019-2029 (US$ Mn)
6.2.2. North America DST Market, by Country, 2019 - 2029 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe DST Market Analysis, 2019 - 2029
6.3.1. Europe DST Market, by Type of Drugs, 2019-2029 (US$ Mn)
6.3.2. Europe DST Market, by Country, 2019 - 2029 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific DST Market Analysis, 2019 - 2029
6.4.1. Asia Pacific DST Market, by Type of Drugs, 2019-2029 (US$ Mn)
6.4.2. Asia Pacific DST Market, by Country, 2019 - 2029 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America DST Market Analysis, 2019 - 2029
6.5.1. Latin America DST Market, by Type of Drugs, 2019-2029 (US$ Mn)
6.5.2. Latin America DST Market, by Country, 2019 - 2029 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) DST Market Analysis, 2019 - 2029
6.6.1. Middle East & Africa DST Market, by Type of Drugs, 2019-2029 (US$ Mn)
6.6.2. MEA DST Market, by Region, 2019 - 2029 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Alexion Pharmaceuticals, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Teva Pharmaceuticals
7.3. Fresenius Kabi AG
7.4. Pharmacia & Upjohn (a subsidary of Pfizer)
7.5. Lupin Ltd.
7.6. Sagent Pharmaceuticals, Inc.
7.7. Zydus Pharmaceuticals, Inc.
7.8. Sandoz Inc. (a subsidiary of Novartis)
7.9. Alkem Laboratories Ltd.
7.10. Mylan Pharmaceuticals, Inc.
7.11. Hoffmann-La Roche/ Chugai Pharmaceutical
7.12. MedImmune LLC
7.13. RemeGen, Ltd.

Companies Mentioned

  • Alexion Pharmaceuticals Inc.
  • Teva Pharmaceuticals
  • Fresenius Kabi AG
  • Pharmacia & Upjohn (a subsidary of Pfizer)
  • Mylan Pharmaceuticals Inc.
  • Chugai Pharmaceutical
  • MedImmune LLC
  • RemeGen Ltd.